SCHEMBL310643

SCHEMBL310643

CCc1cc(N)c(OC)cc1N1CCC(CCS(C)(=O)=O)CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 3/20 0.37
IGF1R P08069 2/20 0.37
HTR4 Q13639 8/20 0.37
ALDH1A1 P00352 3/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
ACHE P22303 3/20 0.35
TSHR P16473 1/20 0.35
INSR P06213 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310907 0.90 IGF1R (0.39) ENPP1IGF1RHTR4ALDH1A1LMNA
SCHEMBL310858 0.87 EGFR (0.38) ENPP1IGF1RHTR4ALDH1A1LMNA
SCHEMBL310912 0.84 SMN1; SMN2 (0.39) ALDH1A1LMNAL3MBTL1MEN1KMT2A
SCHEMBL14406637 0.83 LGMN (0.33) ENPP1IGF1RALDH1A1INSR
SCHEMBL310588 0.81 DRD2 (0.41) HTR4ALDH1A1USP2LMNAHTT
SCHEMBL24781080 0.81 EGFR (0.49) HTR4
SCHEMBL24781110 0.81 HTR4 (0.35) HTR4MEN1KMT2A
SCHEMBL311308 0.79 SMN1; SMN2 (0.41) IGF1RHTR4ALDH1A1USP2LMNA
SCHEMBL310514 0.79 DPP4 (0.41) ENPP1IGF1RHTR4ALDH1A1ACHE
SCHEMBL310526 0.78 EGFR (0.39) IGF1RHTR4ALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 EP disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 ENPP1 703/4885IGF1R 633/4885HTR4 2757/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 ENPP1 703/4885IGF1R 633/4885HTR4 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.